D Dimer Role in Coagulation Activation and Secondary Fibrinolysis
Bruno Pougault, Global Marketing Hemostasis Product Manager at HORIBA, reposted from Horiba on LinkedIn:
”D dimer is an important biomarker of coagulation activation and secondary fibrinolysis that is routinely used to rule out venous thromboembolism (VTE), and to evaluate the risk of VTE recurrence, as well as the optimal duration of anticoagulant therapy.”
Horiba for Healthcare shared on LinkedIn:
”[Register now!] Free Online Workshop
D-Dimer: Diagnostic Challenges and Clinical Relevance
Thursday, October 16, 11–12 AM CEST
Register here.
This online workshop will focus on D dimer, a byproduct of the blood clotting and breakdown process that serves as a marker of ongoing coagulation and fibrinolysis.
The session will explore its clinical use in ruling out deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as the inherent challenges—such as poor specificity, false positives, and difficulties in interpretation, especially in older patients or those with conditions like COVID-19 or cancer.
Participants will learn how to improve diagnostic accuracy and patient management through the use of clinical pretest probability assessments.
The workshop will also discuss the application of age-adjusted D dimer thresholds and the importance of confirmatory imaging in guiding clinical decisions.
Who should attend?
Healthcare professionals involved in D-dimer testing and thromboembolic disease management, such as pathologists, hemostasis lab scientists, acute care nurses, emergency physicians, hospitalists, hematologists, cardiologists, geriatricians, general practitioners, and trainees in related specialties.”
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Jun 10, 2026, 18:22Winai Porntipworawech: The $50 Life-Saving Drug Big Pharma Doesn’t Want You to See
-
Jun 10, 2026, 18:09Leonard Valentino: Innovation in Blood Disorders Being Catalyzed by Pathway to Cures
-
Jun 10, 2026, 18:00Smitirupa Mishra: Normal Hemoglobin Does Not Always Mean Normal Genes
-
Jun 10, 2026, 17:58Talat Uppal: Addressing HMB with RACGP’s Dr. Ramya Raman
-
Jun 10, 2026, 17:52Throw Back Thursday to Past Bruises Posted in the Glanzmann’s Research Foundation
-
Jun 10, 2026, 17:52Priya Prasad: In Massive Hemorrhage, Fibrinogen Is Often the First Clotting Factor to Fall
-
Jun 10, 2026, 17:51Mariam Swidan: Some Red Blood Cells Can’t Handle Pressure
-
Jun 10, 2026, 17:49Ankit Mathur: Hosting ISBT Academy Day on Rare Donor Program in India
-
Jun 10, 2026, 17:48Shadi Tabibian: When Patients Bleed but Standard Testing Is Normal